GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>so of the 30 patients evaluated to date, none had DVT... correct?<

Two of the 14 ATryn patients incorporated from the European trial had DVT, but those cases were asymptomatic and not clinically relevant (i.e. they were detected only with an ultrasound scan).

The primary endpoint of the US trial is non-inferiority of ATryn to plasma-derived antithrombin in clinically relevant DVT; hence “none” is indeed the relevant DVT number for the 30 patients in the ATryn arm evaluated to date.

>how often does DVT happen w/ plasma antithrombin?<

For people with hereditary antithrombin deficiency, the risk of clinically relevant DVT when undergoing surgery or childbirth is in the neighborhood of 30%. Please see #msg-25630072 for details.